| Predicted Trait | |
| Reported Trait | Systolic blood pressure |
| Mapped Trait(s) | systolic blood pressure (EFO_0006335) |
| Additional Trait Information | Score is used in a combined blood pressure score by taking the average between GRS901_SBP and GRS901_DBP |
| Score Construction | |
| PGS Name | GRS901_SBP |
| Development Method | |
| Name | Genome-wide significant variants |
| Parameters | weighted GRSs for all pairwise-independent, LD-filtered (r2 < 0.1) previously reported variants and 535 genome-wide significant SNPs combined |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 884 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000283 |
| Citation (link to publication) | Evangelou E et al. Nat Genet (2018) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 757,601 individuals (100%) |
| PGS Evaluation | |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST006628 Europe PMC: 30224653 |
757,601 individuals | European | NR |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM012835 | PSS009574| European Ancestry| 14,004 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Systolic blood pressure | β: 2.06 [1.79, 2.32] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012836 | PSS009574| European Ancestry| 14,004 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Diastolic blood pressure | β: 1.64 [1.46, 1.81] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012837 | PSS009574| European Ancestry| 14,004 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Pulse pressure | β: 0.42 [0.25, 0.58] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012838 | PSS009574| European Ancestry| 14,004 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Hypertension | OR: 1.27 [1.23, 1.32] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012839 | PSS009575| African Ancestry| 6,970 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Systolic blood pressure | β: 2.38 [1.85, 2.9] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012840 | PSS009575| African Ancestry| 6,970 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Diastolic blood pressure | β: 1.39 [1.09, 1.7] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012841 | PSS009575| African Ancestry| 6,970 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Pulse pressure | β: 0.99 [0.65, 1.32] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012842 | PSS009575| African Ancestry| 6,970 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Hypertension | OR: 1.26 [1.2, 1.33] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012843 | PSS009576| South Asian Ancestry| 8,827 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Systolic blood pressure | β: 2.58 [2.13, 3.03] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012844 | PSS009576| South Asian Ancestry| 8,827 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Diastolic blood pressure | β: 1.49 [1.25, 1.74] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012845 | PSS009576| South Asian Ancestry| 8,827 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Pulse pressure | β: 1.09 [0.8, 1.39] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012846 | PSS009576| South Asian Ancestry| 8,827 individuals |
PGP000283 | Evangelou E et al. Nat Genet (2018) |
Reported Trait: Hypertension | OR: 1.3 [1.24, 1.36] | — | — | — | *Note performance is based on the average between GRS901_SBP and GRS_901_DBP |
| PPM012863 | PSS009584| European Ancestry| 55,439 individuals |
PGP000284 | Tapela NM et al. Eur J Prev Cardiol (2021) |Ext. |
Reported Trait: Uncontrolled hypertension | — | — | Odds Ratio (OR, top vs. bottom quintile): 1.7 [1.6, 1.8] | age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline | 881 SNPs remained after QC |
| PPM012864 | PSS009581| European Ancestry| 55,439 individuals |
PGP000284 | Tapela NM et al. Eur J Prev Cardiol (2021) |Ext. |
Reported Trait: Incident major adverse cardiovascular events in hypertension treatment | — | — | Hazard Ratio (HR, top vs. bottom quintile): 1.13 [1.04, 1.23] | age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline | 881 SNPs remained after QC |
| PPM012865 | PSS009582| European Ancestry| 55,439 individuals |
PGP000284 | Tapela NM et al. Eur J Prev Cardiol (2021) |Ext. |
Reported Trait: Incident myocardial infarction in hypertension treatment | — | — | Hazard Ratio (HR, top vs. bottom quintile): 1.08 [0.97, 1.2] | age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline | 881 SNPs remained after QC |
| PPM012866 | PSS009583| European Ancestry| 55,439 individuals |
PGP000284 | Tapela NM et al. Eur J Prev Cardiol (2021) |Ext. |
Reported Trait: Incident stroke in hypertension treatment | — | — | Hazard Ratio (HR, top vs. bottom quintile): 1.22 [1.06, 1.41] | age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline | 881 SNPs remained after QC |
| PPM013002 | PSS009643| Ancestry Not Reported| 6,335 individuals |
PGP000317 | Parcha V et al. Hypertension (2022) |Ext. |
Reported Trait: Diastolic blood pressure | β: 0.65 | — | — | PGS002258, age, age^2, sex, BMI, randomization arm, history of CVD event, serum creatinine, fasting blood glucose, LDL levels, 10 genetic PCs | *NOTE*: PGS is calculated as an average of PGS002257 and PGS002258 |
| PPM013003 | PSS009643| Ancestry Not Reported| 6,335 individuals |
PGP000317 | Parcha V et al. Hypertension (2022) |Ext. |
Reported Trait: Adverse cardiovascular events | HR: 1.12 [1.02, 1.23] | — | — | PGS002258 | *NOTE*: PGS is calculated as an average of PGS002257 and PGS002258 |
| PPM013001 | PSS009643| Ancestry Not Reported| 6,335 individuals |
PGP000317 | Parcha V et al. Hypertension (2022) |Ext. |
Reported Trait: Systolic blood pressure | β: 1.93 | — | — | PGS002258, age, age^2, sex, BMI, randomization arm, history of CVD event, serum creatinine, fasting blood glucose, LDL levels, 10 genetic PCs | *NOTE*: PGS is calculated as an average of PGS002257 and PGS002258 |
| PPM015498 | PSS009963| European Ancestry| 33,770 individuals |
PGP000376 | Åberg F et al. Sci Rep (2022) |Ext. |
Reported Trait: Liver-related outcome | HR: 1.19 [1.01, 1.24] | — | — | Age, sex, body mass index, waist circumference, weekly alcohol use, fraction of alcohol use as wine, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, diabetes, exercise habits, smoking status (current, former, never smoker) and baseline cardiovascular disease | — |
| PPM020416 | PSS011352| Multi-ancestry (including European)| 23,030 individuals |
PGP000550 | Li C et al. J Glob Health (2023) |Ext. |
Reported Trait: Incident diabetic retinopathy | — | — | Hazard ratio (HR, high vs low PRS tertile): 1.48 [1.21, 1.82] | Age, sex, body mass index, ethnicity, Townsend index, smoking status, alcohol consumption, glycosylated haemoglobin, duration of diabetes, anti-hyperglycaemic medication, anti-hypertensive medication, low-density lipoprotein cholesterol | — |
| PPM020417 | PSS011352| Multi-ancestry (including European)| 23,030 individuals |
PGP000550 | Li C et al. J Glob Health (2023) |Ext. |
Reported Trait: Incident diabetic kidney disease | — | — | Hazard ratio (HR, high vs low PRS tertile): 2.8 [1.57, 4.98] | Age, sex, body mass index, ethnicity, Townsend index, smoking status, alcohol consumption, glycosylated haemoglobin, duration of diabetes, anti-hyperglycaemic medication, anti-hypertensive medication, estimated glomerular filtration rate | — |
| PPM020418 | PSS011352| Multi-ancestry (including European)| 23,030 individuals |
PGP000550 | Li C et al. J Glob Health (2023) |Ext. |
Reported Trait: Incident diabetic neuropathy | — | — | Hazard ratio (HR, high vs low PRS tertile): 1.04 [0.77, 1.42] | Age, sex, body mass index, ethnicity, Townsend index, smoking status, alcohol consumption, glycosylated haemoglobin, duration of diabetes, anti-hyperglycaemic medication, anti-hypertensive medication, estimated glomerular filtration rate | — |
| PPM020415 | PSS011352| Multi-ancestry (including European)| 23,030 individuals |
PGP000550 | Li C et al. J Glob Health (2023) |Ext. |
Reported Trait: Incident diabetic microvascular complications | — | — | Hazard ratio (HR, high vs low PRS tertile): 1.32 [1.11, 1.56] | Age, sex, body mass index, ethnicity, Townsend index, smoking status, alcohol consumption, glycosylated haemoglobin, duration of diabetes, anti-hyperglycaemic medication, anti-hypertensive medication, low-density lipoprotein cholesterol and estimated glomerular filtration rate | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS011352 | — | — | 19,883 individuals | — | European | — | UKB | Median age of full combined ancestry cohort = 61 years; mean follow-up time of full combined ancestry cohort = 11.95 years |
| PSS011352 | — | — | 3,147 individuals | — | Not reported | — | UKB | Median age of full combined ancestry cohort = 61 years; mean follow-up time of full combined ancestry cohort = 11.95 years |
| PSS009574 | — | — | 14,004 individuals | — | European | — | Airwave | — |
| PSS009575 | — | — | 6,970 individuals | — | African unspecified | — | UKB | — |
| PSS009576 | — | — | 8,827 individuals | — | South Asian | — | UKB | — |
| PSS009581 | The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. | Median = 11.5 years | [ ,
51.0 % Male samples |
Mean = 61.0 years | European (white British) |
— | UKB | — |
| PSS009582 | The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. | Median = 11.5 years | [ ,
51.0 % Male samples |
Mean = 61.0 years | European (white British) |
— | UKB | — |
| PSS009583 | The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. | Median = 11.5 years | [ ,
51.0 % Male samples |
Mean = 61.0 years | European (white British) |
— | UKB | — |
| PSS009584 | The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. | Median = 11.5 years | [ ,
51.0 % Male samples |
Mean = 61.0 years | European (white British) |
— | UKB | — |
| PSS009963 | — | Median = 12.9 years | 33,770 individuals, 46.5 % Male samples |
Mean = 49.6 years | European (Finnish) |
Finland | FINRISK, Health2000 | — |
| PSS009643 | Corrected for baseline antihypertensive use | — | 6,335 individuals, 62.7 % Male samples |
Median = 62.1 years Sd = [57.8, 67.1] years |
Not reported | 30.4% non-White individuals | ACCORD | — |